Recruiting

Whole Genome Sequencing

Sponsor:

Nationwide Children's Hospital

Code:

NCT01192048

Conditions

Congenital Heart Disease

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Accepted

Interventions

Blood Sample Collection

Study Details

Brief summary:

Congenital heart disease (CHD) is the most common type of birth defect but the cause for the majority of cardiac birth defects remains unknown. Numerous epidemiologic studies have demonstrated evidence that genetic factors likely play a contributory, if not causative, role in CHD. While numerous genes have been identified by us and other investigators using traditional genetic approaches, these genes account for a minority of the non-syndromic CHDs. Therefore, we are now utilizing whole genome sequencing (WGS), with the addition of more traditional genetic techniques such as chromosomal microarray or traditional linkage analysis, to identify genetic causes of familial and isolated CHD. With WGS we are able to sequence all of the genetic material of an individual and apply different data analysis techniques based on whether we are analyzing a multiplex family or a cohort of trios (mother, father and child with CHD) with a specific isolated CHD. Therefore, WGS is a robust method for identification of novel genetic causes of CHD which will have important diagnostic and therapeutic consequences for these children.

Conditions

Congenital Heart Disease

Study ID

NCT01192048

Start date

Dec, 2009

Status verified date

Apr, 2026

Completion date

Dec, 2030

Anticipated

Primary completion date

Dec, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Subjects must have a diagnosis of Congenital Heart Disease or be related to individuals with Congenital Heart Disease.

Exclusion Criteria:

  • Healthy individuals unrelated to those with Congenital Heart Disease

Study Design

Enrollment

5000 participants

Anticipated

Interventions and Outcome Measures

Arms

Study Subjects

Individuals with Congenital Heart Disease and family members with or without Congenital Heart Disease. A blood sample collection will be required for all study participants.

Interventions

Blood Sample Collection

Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.

Primary outcome measure

  • Identification of novel genetic contributors to congenital heart defects [ Time Frame: up to 3 years, from date of genetic analysis to completion of genetic data analysis or identification of novel genetic contributors, whichever comes first ]

Central Contacts and Locations

Central contacts

Locations

Nationwide Children's Hospital

Recruiting

Columbus, Ohio, United States, 43205

Principal Investigator:

Vidu Garg, MD

More Information

Sponsor

Nationwide Children's Hospital

Last update posted

Apr 7, 2026

Last verified

Apr, 2026

Keywords

  • Congenital Heart Disease
  • birth defect
  • genetics
  • gene
  • DNA
  • direct sequencing
  • microarray
  • single nucleotide polymorphism
  • whole genome array comparative genomic hybridization
  • chromosomal copy number change
  • nucleotide sequence variation
  • exome sequencing
  • whole exome sequencing
  • whole genome sequencing

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Nationwide Children's Hospital on 2026-04-07.